Streptogramins - two are better than one!

Int J Med Microbiol. 2014 Jan;304(1):44-50. doi: 10.1016/j.ijmm.2013.08.008. Epub 2013 Sep 4.

Abstract

Streptogramins are potent drugs against numerous highly resistant pathogens and therefore are used as antibiotics of last-resort human therapy. They consist of a mixture of two different types of chemical substances - the group A streptogramins, which are polyunsaturated macrolactones, and the group B streptogramins, representing cyclic hexadepsipeptides. Streptogramins are unique in their mode of action: each component alone exhibits a moderate bacteriostatic activity by binding to the bacterial 50S ribosomal subunit and thereby blocking translation, whereas the synergic combination of both substances is up to hundred fold more effective than the single compounds, resulting in a bactericidal activity. The streptogramin biosynthetic genes are organized as large antibiotic superclusters. These clusters harbour numerous regulatory genes, which encode different types of regulators that together form a complex hierarchical signalling system, which governs the regulation of streptogramin biosynthesis. Resistance is also regulated by this cascade. However, whereas resistance against streptogramins is quite well understood in diverse pathogenic organisms, only little is known about how the natural producer strains protect themselves against these toxic compounds. Here, we give an overview about the recent advances in streptogramin investigations with a main focus on the best-studied representatives, pristinamycin and virginiamycin. We concentrate on the biosynthesis of these compounds, their regulation and resistance determinants as well as their application in medicine and food industry.

Keywords: 4-N,N dimethylamino-N-methyl-l-phenylalanine; AA-tRNA; ABC; ATP-binding cassette; DMAPA; FDA; GBL; LS(A)P; MFS; MLS(B); MRSA; NRPS; Nonribosomal peptide antibiotic; PI; PII; PKS; PP-tRNA; PTC; Polyketide; Pristinamycin; S(A); S(B); SARP; Streptomyces antibiotic regulatory proteins; Synergism; The U.S. Food and Drug Administration; VM; VREF; VRSA; VS; Virginiamycin; WHO; World Health Organization; amino-acyl-tRNA; lincosamide-streptogramin-pleuromutilin A; macrolide-lincosamide-streptogramin B; major facilitator superfamily antiporter; methicillin-resistant Staphylococcus aureus; nonribosomal peptide synthethase; peptidyl transferase centre; peptidyl-tRNA; polyketide synthase; pristinamycin I; pristinamycin II; streptogramin A; streptogramin B; vancomycin-resistant Enterococcus feacium; vancomycin-resistant Staphylococcus aureus; virginiamycin M; virginiamycin S; γ-butyrolactone.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / biosynthesis
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Biosynthetic Pathways / genetics*
  • Drug Resistance, Bacterial*
  • Drug Synergism
  • Food Industry
  • Humans
  • Microbial Viability / drug effects*
  • Pristinamycin / biosynthesis
  • Pristinamycin / chemistry
  • Pristinamycin / pharmacology*
  • Pristinamycin / therapeutic use
  • Virginiamycin / biosynthesis
  • Virginiamycin / chemistry
  • Virginiamycin / pharmacology*
  • Virginiamycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Pristinamycin
  • Virginiamycin